Welcome to our dedicated page for AbbVie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AbbVie Inc. filings document formal disclosures for a global pharmaceutical issuer with common stock and multiple senior note series registered on the New York Stock Exchange. Recent Form 8-K reports cover quarterly and annual results, preliminary earnings impacts from acquired IPR&D and milestone expenses, material-event disclosures, material agreements and capital-structure updates.
The company’s filing record also includes debt-financing disclosures for completed senior note offerings and definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items. These documents provide regulatory detail on AbbVie’s operating results, listed securities, governance framework and financing activity.
Quaggin Susan E reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Susan E. Quaggin reported a compensation-related award of 71 stock equivalent units tied to AbbVie common stock at a reference value of $217.49 per unit. Following this grant, her balance in these units increased to 784 stock equivalent units.
The units represent director fees credited to a stock equivalent unit account under a grantor trust established by the director and are generally paid in cash at around age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock, and the balance also reflects units accumulated through a dividend reinvestment feature.
RAPP EDWARD J reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Edward J. Rapp received a grant of 155 Stock Equivalent Units on March 31, 2026. The units were credited as director fees at a reference price of $217.49 per unit and are linked to AbbVie common stock performance.
Following this grant, Rapp holds a reported total of 28,865 Stock Equivalent Units. These units are maintained in a grantor trust established by the director and are generally paid in cash at age 65 or upon retirement from the board, with value tracking AbbVie stock, including a dividend reinvestment feature.
Alpern Robert J reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Robert J. Alpern received a grant of 35 stock equivalent units tied to AbbVie common stock as director compensation. The units were credited on the basis of director fees at a reference value of $217.49 per unit and track the return of AbbVie shares.
Following this award, Alpern’s balance increased to 10,369 stock equivalent units held in grantor trust accounts. These units are payable in cash, generally at age 65 or when he retires from the AbbVie board, and the balance also reflects units added through a dividend reinvestment feature.
The Vanguard Group filed Amendment No. 12 to a Schedule 13G/A reporting 0% ownership of AbbVie Inc. The filing states an 0 amount of common shares beneficially owned and shows 0% of the class. The filing explains an internal realignment completed January 12, 2026 that caused certain Vanguard subsidiaries/divisions to report separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
AbbVie Inc. has released its 2026 proxy statement for the May 8, 2026 virtual annual meeting, asking stockholders to elect four Class II directors, ratify Ernst & Young as auditor, approve executive pay on an advisory basis, and back a management proposal to eliminate supermajority voting. The board recommends voting against a stockholder proposal seeking an independent board chair.
The proxy highlights 2025 total net revenues of $61.2BN, growth platform net revenues of $56.6BN, and operating cash flow of $19.0BN, along with 12 blockbuster products and about 90 active clinical and device programs. Over the last decade, AbbVie reports a market capitalization increase of $309BN, quarterly dividend growth from $0.57 to $1.73 per share, and total stockholder return of +485%, outpacing the S&P 500 and NYSE Arca Pharmaceutical Index.
The board emphasizes strong governance and ESG practices, including a majority-independent board with a lead independent director, clawback, anti-hedging and anti-pledging policies, and proxy access. Executive pay is described as heavily performance-based, with more than three-fourths of named executive officer compensation tied to non-GAAP financial, strategic, and long-term equity incentives aligned with stockholder returns.
AbbVie Inc. senior vice president and controller David Ryan Purdue reported a routine tax-related share disposition. On February 27, 2026, 2,108 shares of AbbVie common stock were withheld at $232.08 per share to cover tax obligations, a non-market transaction coded as a tax-withholding disposition.
After this event, Purdue directly held 8,468 shares of AbbVie common stock. He also had an additional 543 shares held indirectly through a profit sharing trust tied to an AbbVie savings program, with that balance stated as of February 20, 2026 and including shares from dividend reinvestment.
AbbVie Inc. is soliciting votes for its 2026 Annual Meeting of Stockholders to be held virtually on May 8, 2026 for holders of record as of March 9, 2026. The proxy lists five voting items: election of directors; ratification of Ernst & Young LLP as independent auditor; an advisory "say on pay" for executive compensation; a management proposal to eliminate supermajority voting thresholds; and a stockholder proposal requesting an independent board chair. The proxy highlights 2025 operational and financial metrics, including $61.2BN total net revenues, $56.6BN growth platform net revenues, $19.0BN operating cash flow, $13.8BN adjusted R&D investment, and a +8.5% operational growth figure. It also cites long-term shareholder returns: +485% total stockholder return over 10 years and a +$309BN increase in market capitalization (as of 12/31/2025). The proxy describes board composition, recent leadership changes including Mr. Robert A. Michael serving as CEO and Chair, governance practices, ESG oversight and disclosures, director nominee biographies, director compensation, securities ownership tables, and the Compensation Discussion and Analysis for named executive officers.
AbbVie Inc. senior vice president and controller David Ryan Purdue sold 5,230 shares of AbbVie common stock in an open-market transaction at $233.56 per share on March 4, 2026. After the sale, he directly held 2,654 shares.
A separate entry shows 543 AbbVie shares held directly in an AbbVie Savings program as of February 20, 2026, with that balance including shares acquired through a dividend reinvestment feature.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice concerning proposed sales of Common shares of ABBV (listed NYSE). The filing lists multiple tranches of Restricted Stock and Performance Shares with date labels and per‑lot quantities such as 426, 392, 377, 293, 386, 496, 1,543, and 1,317. The cover shows a filing date of 03/04/2026.